Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Divi’s Laboratories shares rally 6% on strong Q4 show; should you buy, sell or hold?

      Divi's Labs reported a 23 percent jump in net profit for the three months ended March at Rs 662 crore.

    • Divi's Labs' better-than-expected Q4 results trigger slew of price target upgrades

      Despite brokerages raising price targets for Divi's Labs following its robust performance in Q4, they maintained neutral recommendations on the stock. Their rationale lies in the belief that the current stock valuations already the current stock valuations factor in much of its growth prospects.

    • Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix

      The pharma company is expected to deliver decent earnings in Q4 FY24 aided by strong growth across its generics, nutraceuticals and custom synthesis businesses.

    • Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

      A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi's Labs

    • Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery

      A high base due to strong COVID-sales contribution from Molnupiravir is expected to weigh on Q1 earnings for Divi's Labs.

    • Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill

    • Divi’s Lab Q3FY23 preview: Consolidated net profit to likely drop 44% YoY

    • Divi's Q1 Poll| Solid profit, revenue growth on cards, but costs could dent margin

    • Divis Lab Q1 PAT seen up 27.3% YoY to Rs 709 cr: ICICI Direct

    • Divis Laboratories Q1 PAT seen up 12.5% YoY to Rs 626.8 cr: Prabhudas Lilladher

    • Divis Laboratories Q3 PAT seen up 42.7% YoY to Rs 671.7 cr: Prabhudas Lilladher

    • Divi’s Lab Q1 PAT seen up 8.4% YoY to Rs 533.6 cr: ICICI Direct

    • Divis Q4 PAT seen up 41.1% YoY to Rs. 467.2 cr: Sharekhan

    • Divi’s Q2 PAT may dip 9% YoY to Rs. 363.7 cr: Emkay

    • Divis Q3 PAT seen up 53.5% YoY to Rs. 370 cr: Sharekhan

    • Divi’s lab Q3 PAT seen up 82.3% YoY to Rs. 409.6 cr: ICICI Direct

    • India Inc Q2 review: Earnings breadth deteriorates; margin pressure stark

    • Divis Labs Q2 PAT seen up 45.7% YoY to Rs. 290 cr: HDFC Securities

    • Divis Q2 PAT seen up 39.2% YoY to Rs. 272.5 cr: Sharekhan

    • Divi’s Lab Q2 PAT seen up 33% YoY to Rs. 275.1 cr: ICICI Direct

    • Divi’s Lab Q4 PAT may dip 2.6% YoY to Rs. 280 cr: HDFC Securities

    • Divis Labs Q2 profit seen down 1% on lower operational income and revenue

    • Divis Q3 net likely up 11%, margins may be at 37%

    • Divis Labs Q1 profit seen up 9%; revenue & EBITDA may jump 17%

    • Divis Labs Q1 PAT seen down by 19.5% at Rs 259.3 cr: Religare

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347